



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/531,406	04/14/2005	Stephane Raeppl	02-1019-A1	1207
20306	7590	06/20/2006	EXAMINER	
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP			KUMAR, SHAILENDRA	
300 S. WACKER DRIVE			ART UNIT	
32ND FLOOR			PAPER NUMBER	
CHICAGO, IL 60606			1621	

DATE MAILED: 06/20/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Art Unit: 1621

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-5, 22-26, drawn to compounds and composition, when Ar is non-heterocyclic.

Group II, claim(s) 1-5, 22-26, drawn to compounds and composition when Ar is pyridine.

Group III, claim(s) 6-11, 26-37, drawn to compounds, composition and method of use when R-X is non-heterocyclic.

Group IV, claim(s) 6-11 and 26-37, drawn to compounds, composition and method of use when R-X is morpholine.

Group V, claim(s) 6-11 and 26-37, drawn to compounds, composition and method of use when R-X is pyridine.

Group VI, claim(s) 6-11 and 26-37, drawn to compounds, composition and method of use when R-X is imidazole.

Group VII, claim(s) 6-11 and 26-37, drawn to compounds, composition and method of use when R-X is piperidine.

Group VIII, claim(s) 6-11 and 26-37, drawn to compounds, composition and method of use when R-X is piperazine.

Group IX, claim(s) 12-17, drawn to compounds, when R1 is aryl (non-heterocyclic).

Group X, claim(s) 12-17, drawn to compounds when R1 is benzothiazolyl.

Group XI, claim(s) 12-17, drawn to compounds when R1 is pyrimidinyl.

Group XII, claim(s) 12-17, drawn to compounds when R1 is triazolyl.

Group XIII, claim(s) 12-17, drawn to compounds when R1 is benzodioxolenyl.

Group XIV, claim(s) 12-17, drawn to compounds when R1 is pyridinyl.

Group XV, claim(s) 18-21, drawn to compounds when Ar1 is non-heterocyclic.

Group XVI, claim(s) 18-21, drawn to compounds when Ar1 is morpholinyl.

2. The inventions listed as Groups I-XVI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: compounds of Groups I-VXI are structurally divergent and chemically disparate groups and are able to support patentability individually. A reference anticipating one of the above groups may not render obvious others under 35 USC 103, thus lacking the same or corresponding special technical feature.

3. In view of the complex nature of the restriction requirement, a written restriction requirement has been made.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.


Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHAILENDRA -. KUMAR whose telephone number is (571)272-0640. The examiner can normally be reached on Mon-Thur 8:00-5:30, Alt Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on (571)272-0602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



SHAILENDRA - KUMAR
Primary Examiner
Art Unit 1621

Application/Control Number: 10/531,406
Art Unit: 1621

Page 5

S.Kumar
6/15/06